Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

Company Overview - Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare/orphan diseases [3] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels and at risk of cardiovascular disease [3] Upcoming Event - Esperion will present at J.P. Morgan's 44th Annual Healthcare Conference on January 14, 2025, starting at 2:15 p.m. PT/5:15 p.m. ET [1] - A live webcast of the presentation will be available on the investor and media section of the Esperion website, with a replay accessible approximately two hours after the event [2] Market Position and Strategy - Esperion has a broad U.S. commercial infrastructure and has received global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access [4] - The company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases [4]